Safety Profile of Drugs for Advanced Melanoma: A Report Based on 2008 to 2018 United States Food and Drug Administration Data
| dc.rights.license | open | en_US |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | CASAROTTO, Emilie | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | NOIZE, Pernelle | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | LETINIER, Louis | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | SALVO, Francesco | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | PHAM-LEDARD, Anne | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MOLIMARD, Mathieu | |
| dc.date.accessioned | 2021-03-15T13:29:39Z | |
| dc.date.available | 2021-03-15T13:29:39Z | |
| dc.date.issued | 2020-12-08 | |
| dc.identifier.issn | 1365-2125 (Electronic) 0306-5251 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/26659 | |
| dc.description.abstractEn | We described the safety profiles of all drug classes used for the treatment of advanced melanoma from the United States Food and Drug Administration Adverse Event Reporting System over the period 2008 to 2018. Adverse reactions reported in 25,900 pharmacovigilance cases were described for chemotherapies, immunomodulators, targeted therapies, and immunotherapies. There was a sharp increase in the number of cases over time, with peaks associated with the launch of new treatments. The adverse reactions diversified over time; notably, skin (alopecias, dermatitis) and retinal disorders were frequently associated with targeted therapies and endocrine disorders (hypothalamus, thyroid and adrenal dysfunctions) with immunotherapies. Less well-known reactions were also detected, such as neuropsychiatric disorders with targeted therapies and gastrointestinal ulcers, pneumothorax, and pleural effusions with immunotherapies. The findings highlight the need for various health professionals (including medical specialists or trained nurses) to enhance management of complications. | |
| dc.language.iso | EN | en_US |
| dc.title.en | Safety Profile of Drugs for Advanced Melanoma: A Report Based on 2008 to 2018 United States Food and Drug Administration Data | |
| dc.title.alternative | Br J Clin Pharmacol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1111/bcp.14693 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 33294983 | en_US |
| bordeaux.journal | British Journal of Clinical Pharmacology | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - U1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | PharmacoEpi-Drugs | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03169579 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-03-15T13:29:42Z | |
| hal.export | true | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=British%20Journal%20of%20Clinical%20Pharmacology&rft.date=2020-12-08&rft.eissn=1365-2125%20(Electronic)%200306-5251%20(Linking)&rft.issn=1365-2125%20(Electronic)%200306-5251%20(Linking)&rft.au=CASAROTTO,%20Emilie&NOIZE,%20Pernelle&LETINIER,%20Louis&SALVO,%20Francesco&PHAM-LEDARD,%20Anne&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||